Objectives: To evaluate the efficacy of fidaxomicin treatment, which has a limited effect on the normal gut flora, compared with vancomycin and metronidazole treatment in Clostridium difficile infections (CDIs).
Introduction
Dramatic changes in the epidemiology of Clostridium difficile infection (CDI) in recent years mean that it is now a major public health concern.
1 There was a marked increase in its incidence in Europe, the USA and Canada during the 2000s. In addition, the infections have become more severe and there has been a rise in the number of cases in populations previously thought to be at low risk. 1 The increase in incidence was attributable mainly to the emergence of a new, hypervirulent strain of C. difficile, BI/ NAP1/027 (027), which produces more toxin than other strains. 1, 2 The prevalence of this strain is starting to decrease in some countries; 3, 4 however, this has been accompanied by the emergence of new hypervirulent strains, such as 078. 5 -7 As C. difficile is proving to be genetically facile, this pattern is likely to continue in the future. 1 It is estimated that 3% of healthy adults are colonized with C. difficile, which increases to up to 35% in hospitalized patients. 8 In those residing in long-stay care facilities, CDI prevalence rates may be as high as 50%. 9 The symptoms of CDI can range from mild diarrhoea to abdominal pain, fever and leucocytosis and complications include pseudomembranous colitis, toxic megacolon, septic shock and bowel perforation. 10, 11 Approximately 6% of all patients with CDI experience complications, which rises to 10% -24% in those with severe infection. 12 In very severe cases, CDI can lead to death, but CDI-attributable mortality rates vary between studies, from 0.8% to 21%. 13, 14 Recurrence rates in those with CDI are high: 20% -25% of patients have recurrent disease after treatment is stopped. 15 Furthermore, the risk is cumulative with a higher recurrence rate in those with previous recurrence. 16, 17 Consequently, repeated, prolonged treatment is often necessary. Epidemiological risk factors for recurrence include advanced age, continuation of antibiotics and prolonged hospital stays, while mechanistic risk factors include an inadequate immune response and persistent disruption of the normal colonic flora. 16 Recurrences are of particular clinical importance in the elderly and frail subgroups (e.g. those with renal impairment 18 or cancer 19 ). CDI is associated with a significant economic burden, which is driven mainly by the costs of hospitalization. 20, 21 Across studies, the increase in duration of hospital stay due to CDI ranges from 3.6 to 21.3 days. 14,20 -27 The actual costs associated with CDI vary between studies and are estimated to be between £2900 21 and £4107 20 per patient in the UK. The economic burden of CDI in Europe has been reviewed extensively. 28 Treatment of the index episode of CDI is determined by the severity of symptoms; metronidazole is the mainstay of treatment for mild to moderate infection and vancomycin for severe episodes. 29, 30 However, neither drug is ideally suited for treatment of recurrent infection as metronidazole is associated with CNS neurotoxicity 31 and both drugs are associated with a high recurrence rate ( 25% -30%) 32 due to perturbations in intestinal flora. Fidaxomicin (Dificlir TM ; Astellas) is the first representative of a new class of antibacterials, the macrocycles, characterized by an 18-membered macrocyclic ester structure and inhibitory activity against bacterial RNA polymerase. 33 In vitro, fidaxomicin is at least eight times more active than vancomycin against clinical isolates of C. difficile, including 027 strains. 34 -36 Other properties of fidaxomicin include minimal systemic absorption 37 and limited activity against components of the normal gut flora in vitro 33 -35,37 and in vivo.
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The aim of the current literature-based analysis was to evaluate the clinical efficacy of fidaxomicin versus the alternative standard of care (metronidazole and vancomycin) for the treatment of CDI.
Methods

Study selection
Literature searches were performed between 27 July and 20 August 2011 to identify relevant studies and a second search was carried out on 3 July 2013 to update the findings. The literature databases and the search terms used are summarized in Tables S1 and S2 (both available as Supplementary data at JAC Online). No methodological limitations (including publication date) or filters were applied to the searches, although only articles in English were considered for data extraction. The database searches were supplemented by hand-searching of the bibliographies and abstracts of retrieved records.
The following measures were taken to ensure the rigour of the search and the selection of all relevant studies: the protocol for the search strategy was determined a priori and complied with the requirements of the Scottish Medicines Consortium 39 and the National Institute for Health and Clinical Excellence (NICE); 40 the methodological quality of randomized controlled trials and observational studies was assessed using the criteria recommended by NICE and the Centre for Reviews and Dissemination; 41 non-analytical studies (e.g. case studies and case series) and expert opinion pieces were not included; and the selection of studies for data extraction was conducted by two independent reviewers (Montserrat Casamajor and Cristina Ivanescu, Quintiles Consulting, The Netherlands). If available data were insufficient, the corresponding author of the study was contacted to determine whether the data could be obtained.
Efficacy endpoints
The following efficacy endpoints were evaluated for both analyses: clinical cure (resolution of symptoms and no need for further therapy up to the second day after the end of treatment); recurrence (diarrhoea and a positive result on a stool toxin test any time after the end of treatment); and sustained cure (clinical cure in the absence of any recurrence during the follow-up period) (Figure 1 ). Recurrence could include relapse (same strain) and reinfection (different strain from index episode). In order to align the fidaxomicin studies with the non-fidaxomicin studies, patients with clinical cure who were lost to follow-up or died after the end of treatment were considered to have sustained cure unless a recurrence was reported before loss to follow-up; as reported in a paper published after the current analysis was conducted, this approach did not affect the sustained cure rates for fidaxomicin, but tended to benefit vancomycin. 42 
Efficacy of fidaxomicin versus vancomycin
Direct comparative studies of fidaxomicin and vancomycin were identified and used to evaluate the efficacy of these agents for CDI. In addition, a meta-analysis of data from the direct comparative trials was conducted, both in the overall populations and in specific patient subgroups (nonsevere CDI, severe CDI and first recurrence). For the meta-analysis, the OR was used as the metric of choice. Between-study heterogeneity was evaluated with the x 2 test-based Q statistic and was considered statistically significant at a level of 0.10. We further quantified the effect of heterogeneity across the studies using the I 2 statistic following the guidance of Higgins et al. 43 A naive categorization of values for I 2 would not be appropriate for all circumstances, although we tentatively assigned adjectives of low, moderate and high to I 2 values of 25%, 50% and 75%, respectively. 
JAC
Random-effects models were used where I 2 was ≥50%. Data were analysed using Comprehensive Meta-Analysis Version 2 (Biostat Inc., Englewood, NJ, USA).
Efficacy of fidaxomicin versus metronidazole
From the literature searches conducted, there were no direct comparative studies of fidaxomicin and metronidazole for CDI. For this reason, their relative efficacy was assessed using an adjusted indirect comparison of trials that evaluated fidaxomicin versus vancomycin and metronidazole versus vancomycin.
Adjusted indirect comparisons were performed to yield estimates of the relative differences between fidaxomicin and metronidazole, using vancomycin as a data bridge. To conduct the adjusted indirect comparison for each of the three outcomes of interest, a traditional pairwise meta-analysis was performed for fidaxomicin versus vancomycin and a second such meta-analysis was carried out for metronidazole versus vancomycin. The methodology of Bucher et al. 44 was employed to convert the summary estimates (log ORs) and measures of uncertainty (variances) from the two meta-analyses into an OR and 95% CI representing the difference between fidaxomicin and metronidazole. The null hypothesis was OR BC ¼1 (null relative effect of C versus B) versus the alternative hypothesis OR BC =1 (non-null relative effect of C versus B), where C ¼ fidaxomicin and B¼metronidazole. The methodology of Bucher et al. 44 is a commonly used and well-validated technique for performing adjusted indirect comparisons using a third therapy as a common comparator.
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Results
Search results
The number of articles identified by the literature searches conducted in 2011 and 2013 are shown in Figures S1 and S2 (both available as Supplementary data at JAC Online).
Overall, 36 studies were identified that evaluated the efficacy of fidaxomicin, metronidazole or vancomycin for CDI. Of these, 2 were direct comparative studies of fidaxomicin and vancomycin (n¼1164) 47, 48 and 11 studies compared the efficacy of vancomycin and metronidazole 49 -58 (Table S3 , available as Supplementary data at JAC Online); the remaining 23 studies were not direct comparative studies of these agents. Three vancomycin versus metronidazole studies were included in the meta-analysis (n¼345); 56 -58 reasons for exclusion of the other studies are shown in Table S3 . The duration of the follow-up period (after treatment discontinuation) was 28 days in the two fidaxomicin versus vancomycin studies, 47, 48 21 days in two of the metronidazole versus vancomycin studies 56, 58 and 30 days in the remaining metronidazole versus vancomycin study. 57 
Efficacy of fidaxomicin versus vancomycin
Individual comparative studies
Clinical cure rates, recurrence rates and sustained cure rates for the two identified studies (Study 003 and Study 004) are shown in Table 1 . In both studies, fidaxomicin was non-inferior to vancomycin for clinical cure. The median time to resolution of symptoms for fidaxomicin and vancomycin was 58 and 78 h, respectively, in Study 003 and 50 and 48 h, respectively, in Study 004. Recurrence rates were significantly lower with fidaxomicin than vancomycin in both studies. This was accompanied by a significantly longer time to recurrence with fidaxomicin versus vancomycin: 20 days versus 
Meta-analysis of comparative studies
Study 003 and Study 004 had the same design and dosage regimens. In addition, the treatment arms of both studies were well balanced in terms of demographics and baseline characteristics. Cure was achieved in 88% of patients receiving fidaxomicin compared with 86% of patients receiving vancomycin; the corresponding OR (95% CI) was 1.17 (0.82, 1.66) (heterogeneity: Table 1 .
The results of the meta-analysis according to patient subgroup are shown in Figure 2(b) and the results from the individual studies are shown in Table S4 (available as Supplementary data at JAC Online). Recurrence rates were significantly lower with fidaxomicin versus vancomycin in those with severe and non-severe CDI. Results for sustained cure were significant in the non-severe subgroup; in the severe subgroup, the 95% CI was 0.99-2.26. 
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Efficacy of fidaxomicin versus metronidazole
In the meta-analysis of the three vancomycin versus metronidazole studies, cure rates were 88% and 81%, respectively, recurrence rates were 9% and 10%, respectively, and sustained cure rates were 79% and 71%, respectively, in the overall population. There were no statistically significant differences in any of these parameters (Figure 3a) . Clinical cure and sustained cure rates were significantly higher for vancomycin versus metronidazole in those with severe CDI (Figure 3b) . The indirect comparison showed that the likelihood of recurrence and sustained cure was significantly improved for fidaxomicin versus metronidazole in the overall CDI population (Figure 4) . Similar results were obtained in those with severe CDI. In non-severe infection, sustained cure rates were significantly higher for fidaxomicin versus metronidazole.
Discussion
Metronidazole and vancomycin form the mainstay of treatment for CDI, the former for mild or moderate episodes and the latter for severe CDI episodes. 29, 30 Fidaxomicin is the first in a new class of macrocycle antibiotics with a favourable profile for treating CDI: 
-58
Systematic review it has a narrow-spectrum antibacterial profile and potent bactericidal activity against C. difficile. 33 -35,38 Furthermore, it undergoes minimal absorption 37 and exerts its activity within the gastrointestinal tract. 59 Two Phase III studies with similar designs have been conducted to compare the efficacy of fidaxomicin with that of vancomycin. 47, 48 The results of these studies indicate that fidaxomicin is associated with minor improvements in clinical cure rates versus vancomycin and significant improvements in recurrence rates, time to recurrence and sustained cure. These results were confirmed in the current meta-analysis of the two studies and likely reflect the pharmacological profile of fidaxomicin (and in particular its limited activity against the normal gut flora). 38 As discussed in the accompanying paper, 60 the clinical benefits of fidaxomicin translate into pharmacoeconomic advantages despite its higher acquisition costs versus vancomycin. When data were analysed according to the severity of CDI, recurrence rates were significantly lower with fidaxomicin versus vancomycin in both severe and non-severe CDI patients. There was also a significant difference between treatments in favour of fidaxomicin for sustained cure in the non-severe subgroup; in the severe group, this approached significance (the lower 95% CI was 0.99). There were no significant between-group differences in outcomes in patients with a first recurrence.
To compare fidaxomicin and metronidazole, an indirect comparison was made using data from meta-analyses of studies of fidaxomicin versus vancomycin and vancomycin versus metronidazole. The results obtained for fidaxomicin versus metronidazole were similar to those for fidaxomicin versus vancomycin. There were no statistically significant between-group differences in clinical cure rates; however, fidaxomicin was associated with significantly lower recurrence rates and significantly higher sustained cure rates than metronidazole in the overall CDI population. Once again, the positive effect of fidaxomicin on sustained cure rates versus metronidazole likely reflects its limited effect on the normal gut flora. 38 The results of the subgroup analyses, which showed significantly higher sustained cure rates for fidaxomicin versus metronidazole in severe and non-severe CDI (as well as significantly lower recurrence in severe CDI), should be interpreted with caution given the smaller patient numbers (and hence wide CIs).
The mechanism of action of the positive impact of fidaxomicin on recurrences has not yet been elucidated. As discussed above, it likely reflects the lack of a perturbing effect of fidaxomicin on the normal gut flora, a feature that differentiates it from vancomycin and metronidazole. 38 Consequently, it does not create a favourable environment for any persistent C. difficile spores to germinate in the gut. In addition, compared with vancomycin, fidaxomicin has substantially higher inhibitory activity against C. difficile and a more prolonged post-antibiotic effect. 33 -36,59,61,62 Also, fidaxomicin is bactericidal whereas vancomycin is bacteriostatic 61 and this may contribute to the lower risk of recurrence with fidaxomicin.
There are a number of limitations associated with the current analyses. Only five studies with sufficient data were identified for inclusion in the meta-analyses, two comparing fidaxomicin and vancomycin 47, 48 and three comparing vancomycin and metronidazole. 56 -58 For the latter, only one was double blind and placebo controlled. Two additional studies, which compared with tolevamer, vancomycin and metronidazole, were not included as the data were available only in abstract form at the time of the analysis 55 -future indirect comparisons could therefore be conducted to evaluate the comparative efficacy of fidaxomicin and other treatments such as tolevamer and faecal microbial transplantation. Despite the inclusion of only a small number of studies, an indirect comparison can nevertheless render correct point estimates, although the precision of the estimates will be low. 63 Another limitation is differences in the inclusion criteria between the three vancomycin versus metronidazole studies, Systematic review 2897 JAC potentially introducing heterogeneity in terms of disease severity, course and CDI onset. In addition, the publications do not specify the primary endpoint or report on the power of the studies to detect treatment differences between vancomycin and metronidazole. The follow-up periods used in the studies were also relatively short (≤1 month), which may have had an impact on the estimation of recurrence and, hence, sustained cure rate. The use of indirect comparison methodology to assess the relative efficacy of fidaxomicin versus metronidazole is also a limitation of the study. However, in the absence of head-to-head trials, this is a well-established and accepted method, 45, 46 provided that the following assumptions are met: similarity of treatment effects and homogeneity. 64 In terms of similarity, this was confirmed by the subgroup analysis, which showed that indirect comparison estimates are not different among subgroups, although these data should be interpreted with caution in view of the wide CIs. In terms of homogeneity, the studies included in the indirect treatment comparison were comparable in terms of study design and study population. Furthermore, low heterogeneity was observed as indicated by the I 2 statistic, which was lower than the pre-defined threshold of ≥25% for low heterogeneity for most of the pairwise meta-analyses. We therefore concluded that the five studies were suitably similar to indicate that an adjusted indirect comparison of fidaxomicin versus metronidazole was appropriate.
Another limitation is that the analyses focus on the efficacy of treatment and not safety. Vancomycin is generally associated with only mild adverse events (AEs), although the emergence of vancomycin-resistant enterococci is a concern in those with preexisting colonization. 65 In the two Phase III studies comparing fidaxomicin and vancomycin, the AE profiles of the two agents were broadly similar. 47, 48 Metronidazole is generally well tolerated, but it is efficiently absorbed and has systemic side effects such as nausea, headache, taste disturbances and peripheral neuropathy. 66 In addition, there is a low risk of CNS neurotoxicity and a recent systematic review suggests that this is neither dose nor duration related. 31 This suggests that the side-effect profile of fidaxomicin does not compromise the conclusions of the current efficacy analysis.
The results of the current analysis are consistent with the results of a meta-analysis of the two fidaxomicin versus vancomycin studies published recently. 67 Although the same endpoints [clinical cure, recurrence and sustained (global) cure] were analysed, the Crook et al. 67 meta-analysis did not evaluate these endpoints according to disease severity. The current meta-analysis, therefore, provides additional data to those from Crook et al. 67 on the comparative efficacy of the two drugs. In the Crook et al.
67 meta-analysis, as well as the significant benefits in terms of recurrence and sustained cure, fidaxomicin significantly reduced the composite endpoint of persistent diarrhoea, recurrence or death by 40% versus vancomycin through to day 40 (95% CI: 26, 51; P,0.0001).
The comparative efficacy of vancomycin and metronidazole has been reported in previous systematic reviews. In the Cochrane review published in 2011, which included only randomized controlled trials, no statistically significant differences in efficacy were found between vancomycin and metronidazole. 68 In a more recent review, which included 39 articles (7005 patients), treatment failure rates were 22.4% with metronidazole (16 studies) and 14.2% with vancomycin (8 studies) and recurrence rates were 27.1% (18 studies) and 24.0% (8 studies), respectively. The authors acknowledge that there was variability in reported outcomes between studies, depending on factors such as study design, location and follow-up period. 32 In conclusion, the current analyses indicate that fidaxomicin offers significant benefits in terms of patient outcomes compared with vancomycin. Indirect comparisons indicate that the same is also true for fidaxomicin compared with metronidazole. These data suggest that in the absence of a randomized controlled trial of fidaxomicin versus metronidazole, fidaxomicin should be considered as a potential first-line treatment for CDI, rather than as a second-or third-line treatment after vancomycin and metronidazole. The results also support the first-line use of fidaxomicin in those with severe infection. Further analyses of fidaxomicin versus metronidazole in non-severe disease, including a comparison of safety and tolerability, are required.
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